BOC Sciences Rolled Out PEG GMP Manufacture Services for Broad Applications

BOC Sciences recently launched the PEG GMP manufacture service, a novel solution that aims at providing GMP-grade PEG products for a wide scope of applications. - December 30, 2022 - BOC Sciences

The Catholic Children’s Home Receives a Christmas Surprise

ProCare Health Embraces the Gift of Giving - December 23, 2022 - ProCare Health

Paras Biopharmaceuticals Creates Excellence with “Continuous Biomanufacturing”: Achieves Objectives of “High Productivity & Biomanufacturing Innovation”

Paras Biopharmaceuticals Creates Excellence with “Continuous Biomanufacturing”: Achieves Objectives of “High Productivity & Biomanufacturing Innovation”

With 6 years of dedicated work at Paras Biopharmaceuticals and the use of Paras Biopharmaceuticals’ unique technology platform (which comprises of Bioproduction technologies for economical production of biologics), the company is pleased to announce that an excellent scale-up production process is achieved with “Continuous Biomanufacturing.” - December 19, 2022 - Paras Biopharmaceuticals Finland Oy

Solex Thermal Science Commits to UN Global Compact

New report illustrates progress on sustainability development goals. - December 17, 2022 - Solex Thermal Science

Paras Biopharma Streamlines Offerings as “Biologics CDMO” and Biosimilar Co-Development as “Paras Biologics”

Paras Biopharma Streamlines Offerings as “Biologics CDMO” and Biosimilar Co-Development as “Paras Biologics”

Paras Biopharmaceuticals Finland Oy today revealed that the company has streamlined and enhanced its business activities with the establishment of a division called, Paras Biologics. In addition to its existing biologics CDMO activities and capabilities (this division is now referred to as Paras Biopharma), the creation of Paras Biologics enhances the company’s biologics and biosimilar pipeline for co-development and licensing opportunities. - December 11, 2022 - Paras Biopharmaceuticals Finland Oy

PharmStars Announces Fall 2022 Accelerator Graduates: 11 Digital Health Startups Complete PharmStars’ Pharma-Focused Accelerator Program

PharmStars Announces Fall 2022 Accelerator Graduates: 11 Digital Health Startups Complete PharmStars’ Pharma-Focused Accelerator Program

PharmStars, the pharma-focused accelerator for digital health startups, announces the graduation of 11 startups from its Fall 2022 program focused on “Innovations in Real-World Evidence.” The graduating startups successfully completed PharmaU, PharmStars’ 10-week education, and mentoring program. PharmaU culminated with a Showcase Event--held in Boston in early November--that brought together the participating startups and PharmStars’ seven innovation-minded pharma members. - December 08, 2022 - PharmStars

IVL Creates New Supplement for Optimized Nitric Oxide Support and Better Blood Flow

IVL Creates New Supplement for Optimized Nitric Oxide Support and Better Blood Flow

4 ingredients to support the body's production of Nitric Oxide, a vital molecule for maintaining healthy muscles and blood vessels. - December 08, 2022 - IVL.com

PharmStars Announces “Innovations in Women’s Health and Health Equity” Theme for Spring 2023 Accelerator

PharmStars Announces “Innovations in Women’s Health and Health Equity” Theme for Spring 2023 Accelerator

PharmStars, the pharma-focused accelerator for digital health startups, is now accepting applications for its Spring 2023 cohort with the theme “Digital Innovations in Women’s Health and Health Equity.” Startups with digital innovations that promote more equitable, inclusive healthcare for underserved population or focused on women’s health (e.g., breast, ovarian, and cervical cancer; gynecological conditions; osteoporosis; menopausal, hormonal, and reproductive conditions) are welcome to apply. - December 05, 2022 - PharmStars

Clinical Research Organization, Huntington Study Group “Firsts” Continue

Clinical Research Organization, Huntington Study Group “Firsts” Continue

The Huntington Study Group (HSG), a world leader in conducting clinical trials for Huntington’s Disease (HD) through its Clinical Research Organization (CRO), HSG Clinical Research, Inc. (HSGCR) continues making groundbreaking progress in the HD world. At their Annual Meeting in November, the... - December 05, 2022 - Huntington Study Group

Westside Finishing Co., Inc. Achieves PCI 3000 Re-Certification

Westside Finishing Co., Inc. is proud to announce the achievement of PCI 3000 recertification, marking 7 consecutive years of certified status. The PCI 3000 Certification Program, administered by The Powder Coating Institute (PCI), is an extensive audit program that evaluates a custom... - December 02, 2022 - Westside Finishing Inc.

NaturaLawn of America Welcomes New Marketing Director

NaturaLawn of America Welcomes New Marketing Director

NaturaLawn® of America is a national lawn care franchise system with 35 owners holding 99 licenses, servicing over 125,000 customers in 26 states welcomes a strategic Director of Marketing. - December 01, 2022 - NaturaLawn of America

Paras Biopharmaceuticals Finland Oy is Highly Recommended for Biologics CDMO – Development / Scale-up & Production of Biologics by Innovative USA Biopharma Company

Paras Biopharmaceuticals is pleased to announce that the company has been highly recommended for its Biologics CDMO – development / scale-up and production capabilities. The Paras Biopharmaceuticals Team has successfully completed multiple biologics projects in 2022. - November 29, 2022 - Paras Biopharmaceuticals Finland Oy

Huntington Study Group Annual Meeting

Huntington Study Group Annual Meeting

The Huntington Study Group (HSG), a world leader in conducting clinical trials for Huntington’s Disease (HD), recently held its 29th Annual Meeting in Tampa, FL. This renowned meeting brings together HD thought leaders, scientific experts, industry partners and sponsors, advocacy groups, and... - November 29, 2022 - Huntington Study Group

Marty Rosenberg joins the Board of Scientific Advisors at Microvascular Therapeutics.

Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, Arizona, announced the appointment of Marty Rosenberg to the MVT Board of Scientific Advisors. Mr. Rosenberg brings a broad experience with the clinical development and global regulatory approval process for... - November 25, 2022 - Microvascular Therapeutics, Inc.

David Lim Joins the Team at Microvascular Therapeutics as Director of Finance

Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, Arizona, announced the appointment of David Lim as Director of Finance at MVT. Mr. Lim brings a broad experience with the business development and strategic financing for diagnostic pharmaceuticals across all... - November 25, 2022 - Microvascular Therapeutics, Inc.

Novugen Pharma Became the First Pharmaceutical Company in Malaysia to Receive USFDA Approval for Its Manufacturing Facility

Novugen Pharma Became the First Pharmaceutical Company in Malaysia to Receive USFDA Approval for Its Manufacturing Facility

The Company was audited in September 2022 and USFDA issued an Establishment Inspection Report (EIR) in November 2022. Novugen Pharma is the first USFDA approved pharmaceutical manufacturing in Malaysia and the only in Southeast Asia. - November 22, 2022 - Novugen

Introducing MIRAPeel MD, the Only 6-in-1 Clinical-Grade Skincare Platform of Its Kind

Introducing MIRAPeel MD, the Only 6-in-1 Clinical-Grade Skincare Platform of Its Kind

Attention Dermatologists, Plastic Surgeons and Med Spa Owners: Meet MIRAPeel MD, the one stop shop for all skin needs, and the first of its kind. Offering 6 treatments in one, MIRAPeel MD is setting a new treatment standard for skin care specialists, medical spas, dermatology and plastic surgery offices. - November 22, 2022 - eMIRAmed

Immunodominant Announces Call for Initial Investment Round as Company Prepares for Phase 2 Study of Oral OTC COVID-19 Drug

Immunodominant Inc., a drug discovery and development company engaged in progressing innovative research from academia to commercialization, today announced its intention to begin an initial financing round of up to $30 million. Immunodominant also announced today that it is scheduling a Phase 2 clinical study after a pre-IND meeting with the FDA for LACTOVID, a novel, oral, over-the-counter drug for the prevention and treatment of COVID-19. - November 20, 2022 - Immunodominant

Garrison Minerals' Products Now NSF-Certified

Garrison Minerals' Products Now NSF-Certified

Garrison Minerals is excited to announce the formal certification of the AlkapHix®, MaripHix™, and OxipHix® product lines by the National Sanitation Foundation (NSF International) and the American National Standards Institute (ANSI). - November 18, 2022 - Garrison Minerals

Microvascular Therapeutics Receives Funds from the National Cancer Institute (NCI) for Its Brain Tumor Program

Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, AZ, was recently awarded a Phase I Small Business Innovation Research grant from the National Cancer Institute (NCI). Emmanuelle Meuillet, Chief Scientific and Operating Officer at MVT said, “We are... - November 18, 2022 - Microvascular Therapeutics, Inc.

Prosel Bioscience Becomes One Cell Foods and Names Dr. Scott Jenkins Its New CEO

Prosel Bioscience Becomes One Cell Foods and Names Dr. Scott Jenkins Its New CEO

One Cell Food, Inc will focus on scaling its proprietary bioreactor design to commercialize developed strains for its first food product by early 2023. As the new CEO, Dr. Scott Jenkins will lead the operation and fundraising efforts. - November 17, 2022 - One Cell Foods, Inc.

DASH Leverages Automated Solutions

Artificial Intelligence Tools Combined with Proven ERP Creates a Powerful Platform for Businesses. - November 17, 2022 - Dash Development

Alpyne Strategy to Host Refrigerant Briefing for Fall 2022

Alpyne Strategy, a leading industrial marketing agency in Murfreesboro, TN, will host a Refrigerant Briefing for Fall 2022 live webinar event on Friday, Dec. 9 at 12:00pm CST. In this 1-hour session, HVAC-R stakeholders can learn the top refrigerant insights from this fall. Topics of discussion... - November 14, 2022 - Alpyne Strategy

Families of World War II Veterans Holds 2022 Fundraising Golf Tournament

Families of World War II Veterans held its annual golf tournament and fundraising event on Monday, October 24, at the award-winning Trinity Forest Golf Club in Dallas, Texas, the former home of the renowned AT&T Byron Nelson tournament. This is the organization’s biggest fundraising event... - November 12, 2022 - Careington

Are You Ready to Get Shroomed?

Are You Ready to Get Shroomed?

After a historical win for the war on drugs in Colorado, the state and the nation begins to look at ways to implement Magic Mushroom assisted therapy along with other plant medicine. We look at the facts behind this, and what it means for you. - November 11, 2022 - shroomed

BOC Sciences: ADC Analysis and Characterization Support Development, Registration, and Release

BOC Sciences announces support for antibody-drug conjugate (ADC) development, registration, and release by providing a comprehensive set of analysis and characterization technologies. - November 11, 2022 - BOC Sciences

BOC Sciences Makes Easy Access to Polymerization Tech

Owing to the continuously upgraded synthesis technologies and analytical abilities, BOC Sciences has performed well in the polymer industry, serving the community with a comprehensive product portfolio and valuable technical support. - November 11, 2022 - BOC Sciences

PharmStars Announces Fall 2022 Startup Showcase Event

PharmStars Announces Fall 2022 Startup Showcase Event

PharmStars, the pharma-focused accelerator for digital health startups, announces that its Fall 2022 Showcase Event will begin on November 8, 2022. The Showcase is the culmination of a 10-week startup accelerator program. At the Showcase Event, startups will make formal presentations to and meet... - November 08, 2022 - PharmStars

Biomed Industries, Inc. (“Biomed”) Today Announced the Closing of Its Merger with MedAware Systems, Inc., (“MedAware”)

Biomed Industries, Inc. (“Biomed”) today announced the closing of its merger with MedAware Systems, Inc., (“MedAware”), in which all issued and outstanding common shares of capital stock of MedAware will be exchanged for common stock of Biomed at a ratio of 5.33 shares of MedAware for 1 new common share of Biomed. The transaction valued at an aggregate of $20 million, to be paid by 2,259,170 common shares of Biomed. At present, Biomed has approximately 76,354,075 common shares issued. - November 07, 2022 - Biomed Industries, Inc.

Thrivous Launches Vitality Geroprotector Formula 2

Thrivous, the human enhancement company, has released Vitality Geroprotector Formula 2 with Mirtoselect® Blueberry Anthocyanin. Vitality is the advanced geroprotector supplement that Thrivous develops to enhance metabolism and cell function for better aging. Vitality combines geroprotector... - November 07, 2022 - Thrivous

Thaddeus Medical Customizable Cold-Chain iQ-Ler Now Available for Pre-Order

Thaddeus Medical Customizable Cold-Chain iQ-Ler Now Available for Pre-Order

Cold Chain system is designed for storage, transportation and dispensary of temperature-sensitive medical therapeutics to eliminate all spoilage in cold-chain logistics and improve patient outcomes - November 03, 2022 - Thaddeus Medical

Beaulieu International Group Acquires Leading US Synthetic Turf Manufacturer Act Global, Strengthening Its Position in the Growing Market for Sports Turf

Through this acquisition, B.I.G. strengthens its position in the global artificial grass market, especially in the sports segment. Act Global has close to 300 certified fields installed and holds soccer (FIFA), hockey (FIH) and rugby (WR) certifications. No financial details are disclosed on the transaction. - November 02, 2022 - Act Global

DistillerSR Launches New CuratorCR Capabilities to More Dynamically Manage and Reuse Evidence-Based Research

CuratorCR Knowledge Center Provides Alternative to Elsevier’s QUOSA Virtual Library as Its Sunset Date Looms. - October 31, 2022 - DistillerSR

Gallant Announces Hiring of John Klacking, Ph.D. as Chief Business Officer

Furthering its regenerative medicine therapeutics research and development, animal biotech company Gallant welcomes a pioneer in the biotech space. - October 25, 2022 - Gallant

Huntington Study Group Announces Results from the HD-Net Assessment on the State of Care for Huntington’s Disease in the United States

Huntington Study Group Announces Results from the HD-Net Assessment on the State of Care for Huntington’s Disease in the United States

The Huntington Study Group (HSG), a world leader in clinical research for Huntington’s Disease (HD) for over 30 years, is pleased to announce the results from the novel HD-Net survey, which examined the United States Huntington’s disease (HD) care delivery in a variety of clinic settings by HD specialists and non-specialists. - October 25, 2022 - Huntington Study Group

Minus K Technology Announces Announces Its Seventh U.S. Educational Giveaway of Vibration Isolators to Colleges and Universities

As Minus K celebrates their upcoming 30 years in business, they are giving away $25,000* dollars worth of passive mechanical patented superior performing negative-stiffness low-frequency vibration isolators to colleges in the United States. - October 25, 2022 - Minus K Technology Inc.

Vivisum Partners Publishes Strategic Analysis on the Ulcerative Colitis Marketplace

Among branded ulcerative colitis treatments, 84% of US gastroenterologists expect Zeposia to see an increase in prescription volume over the next 12 months, according to new research on the ulcerative colitis marketplace published by Vivisum Partners. Vivisum Partners has just published its... - October 25, 2022 - Vivisum Partners, LLC

New Market Insights on the Best MS Treatment Published by Vivisum Partners

What’s the best MS treatment according to neurologists? The question of how to assess the ideal drug to treat multiple sclerosis is difficult to answer. Neurologists determine which clinical attributes take higher priority for each patient. Vivisum Partners, LLC, a market research firm in... - October 24, 2022 - Vivisum Partners, LLC

ARA Breast Radiologist Goes All Pink to Emphasize Importance of Mammography

ARA Breast Radiologist Goes All Pink to Emphasize Importance of Mammography

It’s Breast Cancer Awareness Month and many are working to bring attention to breast cancer and the importance of screening with mammography. However, Dr. Arthy Saravanan, head of the breast imaging section at ARA Diagnostic Imaging, is going the extra mile, in a bright pink car. Dr. - October 18, 2022 - ARA Diagnostic Imaging

Huntington Study Group Announces myHDstory™ Pilot Study: Making HD Voices Heard Has Reached Target Enrollment

Huntington Study Group Announces myHDstory™ Pilot Study: Making HD Voices Heard Has Reached Target Enrollment

The Huntington Study Group (HSG), a world leader in clinical research for Huntington’s Disease (HD) for over 30 years, is pleased to announce that the pilot study, Making HD Voices Heard, on the new online research platform, myHDstory™, has reached its enrollment target. “The HSG... - October 18, 2022 - Huntington Study Group

Kantify and Mcule Harness the Power of Data to Accelerate Drug Discovery

Kantify and Mcule Harness the Power of Data to Accelerate Drug Discovery

Kantify, using its AI technology for drug discovery and Mcule, with its compound sourcing platform, are collaborating to leverage data for better hit prediction. - October 17, 2022 - Mcule

Thrivous Releases Serenity Nightly Nootropic Formula 3

Thrivous, the human enhancement company, has released Serenity Nightly Nootropic Formula 3 with KSM-66® Ashwagandha. Serenity is the advanced nootropic supplement that Thrivous develops to enhance relaxation, sleep, and next-day focus. Serenity combines nootropic nutrients with the highest... - October 14, 2022 - Thrivous

High-Standard Fermented Raw Materials That Satisfy the Quality Attributes of Healthcare Products

BOC Sciences is able to provide clients with high-standard fermented raw materials that satisfy the quality attributes of finished healthcare products. - October 13, 2022 - BOC Sciences

Huntington Study Group Enrolls First Participant for Its Observational Study to Test the Reliability of the Virtual Use of the Unified Huntington’s Disease Rating Scale

Huntington Study Group Enrolls First Participant for Its Observational Study to Test the Reliability of the Virtual Use of the Unified Huntington’s Disease Rating Scale

The Huntington Study Group (HSG), a world leader in conducting clinical trials for Huntington’s Disease (HD) for over 30 years, together with its Clinical Research Organization (“CRO”), the HSG Clinical Research, Inc., today announces the enrollment of the first participant of its... - October 12, 2022 - Huntington Study Group

BOC Sciences Declares the Availability of 10,000 Impurities, All in Stock

BOC Sciences recently confirmed to its customers that over 10,000 impurities are now in stock, ready for immediate delivery. - October 12, 2022 - BOC Sciences

Mirror Biologics, Inc. Announces Additional $20 Million Investment to Close Out $30 Million Series A Investment Round

Mirror Biologics, Inc. Announces Additional $20 Million Investment to Close Out $30 Million Series A Investment Round

Mirror Biologics, Inc., a clinical stage biopharmaceutical company today announced the completion of the final $20 million tranche of its $30 million Series A investment round with Bradbury Asset Management (Hong Kong), Limited. Bradbury provided an initial $10 million tranche for this round in... - October 11, 2022 - Mirror Biologics, Inc.

SYNG Pharmaceuticals Announces Issuance of Its Canadian Patent for Non-Hormonal Therapy for Endometriosis

SYNG Pharmaceuticals Inc. (SYNG), a Kingston, Ontario based women’s health biotech, is pleased to announce that on October 04, 2022, the Canadian Intellectual Property Office granted Canada Patent No. 2,903,608 titled, "Treatment of endometriosis, angiogenesis and/or endometrial lesion growth." - October 09, 2022 - SYNG Pharmaceuticals Inc.

Vivisum Partners' Research Finds New Ulcerative Colitis Drugs Provide Excitement to Gastroenterologists

Newly published research found that several new ulcerative colitis drugs currently in development are providing excitement among gastroenterologists eager to add additional medicines to their current treatment options. Based on a market analysis from Vivisum Partners, a market research and brand... - October 08, 2022 - Vivisum Partners, LLC

Tasly Pharmaceuticals to Exhibit at BioJapan 2022 -- Bio-Pharmaceutical Company to Join with Maryland-Based Organizations at Asia’s Premier Biotechnology Partnering Event

Tasly Pharmaceuticals to Exhibit at BioJapan 2022 -- Bio-Pharmaceutical Company to Join with Maryland-Based Organizations at Asia’s Premier Biotechnology Partnering Event

Tasly Pharmaceuticals will exhibit at BioJapan 2022, October 12-14 at PACIFICO Yokohama - October 05, 2022 - Tasly Pharmaceuticals, Inc.

Professional Plastics Expands U.S. Northeast Distribution Capabilities

Professional Plastics Expands U.S. Northeast Distribution Capabilities

A new facility in Angola doubles the company’s footprint in Western New York and advances its development of a distribution hub and continued growth in the region. - October 05, 2022 - Professional Plastics

Press Releases 451 - 500 of 6,215